The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Women on Osteoporosis Drugs Still Need Bone Density Screenings

Women on Osteoporosis Drugs Still Need Bone Density Screenings

July 18, 2016 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Women with osteoporosis who take bisphosphonates to help avoid fractures still need to have their bone density monitored, a Canadian study suggests.

You Might Also Like
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Zoledronic Acid May Improve Bone Density in Elderly Women
  • Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

Researchers who studied more than 6,600 women taking osteoporosis drugs found that for nearly one in five, bone mineral density at the hip actually decreased after the women started taking the medication.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The hip “is an excellent site for monitoring bone mineral density because it predicts fractures, can be measured with great reliability making it easier to detect small changes, and is not affected by age-related problems like spinal arthritis,” says lead study author Dr. William Leslie, a radiology researcher at the University of Manitoba.

The findings suggest it may be time for some physicians to rethink their reluctance to get women bone mineral density tests after they start medication, Leslie says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Whether to send women for dual-energy x-ray absorptiometry (DEXA) after they start therapy “has been controversial,” he adds by email. “It is relatively inexpensive, but adds to the cost of care while there has been little scientific data to answer the question of whether a change in bone mineral density while receiving treatment tells us anything about that person’s ongoing fracture risk.”

For the current study, researchers followed women for an average of 9.2 years starting when they were typically around 64 years old. Most of the women were prescribed bisphosphonates, such as Fosamax (alendronate sodium), Actonel (risedronate sodium) and Boniva (ibandronate sodium).

Overall, 910 women, or about 14%, experienced fractures during the study period, including 198 with hip fractures, researchers report in the Annals of Internal Medicine, July 18.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Bone mineral density tests of the hip showed that about 30% of the women experienced an increase in density after they started taking drugs and another 19% of these women had decreases.

Compared with women with similar hip bone mineral density before and after starting osteoporosis drugs, the fracture risk for women with a decrease in total hip bone mineral density was 2.9% higher after five years and 5.5% higher after 10 years.

In contrast, the risk of fractures was 1.3% lower at five years and 2.6% lower at 10 years for women whose bone mineral density increased during the study.

One limitation of the study is that women didn’t all wait the same amount of time between their initial bone mineral density tests and follow-up scans, the authors note.

The researchers, therefore, can’t say what the best retesting regimen would be.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bisphosphonates, bone mineral density (BMD), Osteoporosis, osteoporosis treatments, Women

You Might Also Like:
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Zoledronic Acid May Improve Bone Density in Elderly Women
  • Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)